Full-Time

Validation Specialist

Confirmed live in the last 24 hours

Viatris

Viatris

10,001+ employees

Global healthcare company providing medicines access

No salary listed

Junior, Mid

Dublin, Ireland

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Minitab
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Viatris referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor's degree in Science, Engineering, Technology or a related discipline.
  • At least 2 years of hands-on experience working as a validation engineer/specialist in a cGMP environment, preferably in an oral solid dose facility.
  • Good knowledge with Minitab SW.
  • Full understanding of cGMP requirements, including Annex 11 and Annex 15.
  • Effective technical writing skills.
  • Excellent interpersonal, leadership, communication (written and verbal) and time-management skills.
  • Flexible and able to manage multiple priorities simultaneously.
Responsibilities
  • Process Validation/Qualification projects will be across a range of production areas which may include Process, Cleaning, Software, Utility and Facility projects.
  • Generation, execution and close out of validation projects relating to existing products and new product introductions.
  • Ongoing process validation program, by drafting OPV protocol & report and assess the process stability and capability.
  • Participate in project teams and assist in determining project schedules and the appropriate levels of validation.
  • Execution and documenting risk assessments (FMEA) with respect to validation activities.
  • Perform validation functional testing as required. Track and resolve deviations during qualification activities.

Viatris provides a wide range of healthcare products, focusing on both generic and brand-name medications to meet global health needs. Their extensive portfolio includes high-quality medicines that address various health conditions, from acute illnesses to chronic diseases. Viatris operates a global supply chain that ensures these medicines are accessible to patients when and where they need them. Unlike many competitors, Viatris combines the strengths of generics and brands, allowing them to serve a diverse patient population effectively. The company's goal is to empower individuals to lead healthier lives at every stage, aiming to reach approximately 1 billion patients worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Viatris benefits from the rise of value-based healthcare models, aligning with patient outcomes.
  • Expansion in emerging markets offers Viatris opportunities to reach underserved populations.
  • Focus on digital health solutions could expand Viatris' service offerings significantly.

What critics are saying

  • Increased competition from biosimilars threatens Viatris' market share in key areas.
  • Ongoing patent expirations lead to revenue declines as generics enter the market.
  • Fluctuating foreign exchange rates pose financial risks to Viatris' global revenue streams.

What makes Viatris unique

  • Viatris bridges the gap between generics and brands, offering a unique healthcare approach.
  • The company has a strong global presence, enhancing its market reach and influence.
  • Viatris' diverse portfolio includes innovative licensing agreements, like with Lexicon Pharmaceuticals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PR Newswire
Mar 28th, 2025
Viatris To Report First Quarter 2025 Financial Results On May 8, 2025

PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 3rd, 2025
Viatris To Report Fourth Quarter And Full Year 2024 Financial Results On February 27, 2025

PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc